drugset

drugset / Trial / NCT00229736

A Study of AAV-hAADC-2 in Subjects With Parkinson's Disease

NCT00229736 ↗

Phase 1 Completed 10 enrolled Genzyme, a Sanofi Company

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Safety Study in subjects with Parkinson's Disease

Timeline

Start: 2004-11
Primary completion: 2013-03
Completion: 2013-03

Publications

Background Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins RA, VanBrocklin HF, Wright JF, Bankiewicz KS, Aminoff MJ. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology. 2009 Nov 17;73(20):1662-9. doi: 10.1212/WNL.0b013e3181c29356. Epub 2009 Oct 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AAV-hAADC-2	Gene therapy (AAV / viral vector)	9e+10 vg	Other
Subject	AAV-hAADC-2	Gene therapy (AAV / viral vector)	3e+11 vg	Other

Indications